Beta-blocker heart attack trial: design, methods, and baseline results. Beta-blocker heart attack trial research group.
The Beta-Blocker Heart Attack Trial (BHAT) was a multicentered, double-blind, randomized, placebo-controlled clinical trial designed to test the efficacy of long-term therapy with propranolol given to survivors of an acute myocardial infarction (MI). Three thousand, eight hundred and thirty-seven men and women, aged 30-69 years, were randomized into either the propranolol or placebo group 5 to 21 days after hospital admission for the MI and were followed at quarterly visits for 12 to 40 months (mean = 25 months). The primary outcome for the trial was all-cause mortality. This article describes the design and baseline findings of the trial. Included is a description of the historical background for the trial and the procedures employed in patient recruitment, randomization, treatment and follow-up. Also included is a comparison between the BHAT population and post-myocardial infarction patients enrolled in the other long-term trials of beta-blockers.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010919:Placebos; D011433:Propranolol / Q000627:therapeutic use; D011897:Random Allocation; D012008:Recurrence
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D011433:Propranolol